Results 131 to 140 of about 23,963 (194)

Association of cytokine levels with treatment duration and patient family history in Egyptian multiple sclerosis patients. [PDF]

Sci Rep
Mohsen E, Haffez H, Ahmed S, El-Mahdy TS, Hamed S.   +4 more
europepmc   +1 more source

Fingolimod potentiates the antifungal activity of fluconazole against fluconazole-resistant <i>Candida auris</i>. [PDF]

Front Cell Infect Microbiol
Bae JH, Eom YB.
europepmc   +1 more source

Rituximab-Induced Serum Sickness in Patients With Multiple Sclerosis: A Case Report and Literature Review. [PDF]

Cureus
Sikkal A, Ouahmane S, El Otmani H, El Moutawakil B, Rafai MA.   +4 more
europepmc   +1 more source

Fingolimod Improves Anxiety-like Behavior and Modulates Sphingosine-1-Phosphate Receptors Gene Expression in a Diabetic Mouse Model. [PDF]

Biomolecules
Wencel PL, Blecharz-Klin K, Piechal A, Pyrzanowska J, Mirowska-Guzel D, Strosznajder RP.   +5 more
europepmc   +1 more source

Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity. [PDF]

Mult Scler
Sandgren S, Maceski AM, Benkert P, Einsiedler M, Schaedelin S, Oechtering J, Achtnichts L, Lalive PH, Müller S, Pot C, Heslegrave A, Hunt D, Lycke J, Hoepner R, Roth P, Gobbi C, Comabella M, Derfuss T, Derfuss T, Kappos L, Granziera C, Abdelhak A, Leppert D, Willemse EA, Zetterberg H, Kuhle J.   +25 more
europepmc   +1 more source

Safety of disease-modifying therapies in multiple sclerosis: real-world data from the Austrian MS Treatment Registry (AMSTR). [PDF]

J Neurol
Monschein T, Untersteiner H, Ponleitner M, Krajnc N, Zrzavy T, Bsteh G, Rommer P, Kornek B, Enzinger C, Di Pauli F, Kraus J, Guger M, Leutmezer F, Berger T, Austrian MS Treatment Registry (AMSTR).   +14 more
europepmc   +1 more source

Terápiás továbblépés dilemmája relapszáló-remittáló sclerosis multiplexben az első vonalbeli kezelés hatástalansága esetén: fingolimod vagy natalizumab? [PDF]

, 2014
Lovas, Gábor
core  

Immunogenicity of Hepatitis B Virus Vaccination in Relapsing-Remitting Multiple Sclerosis Patients Under Immunocompromising Treatment. [PDF]

Int J Mol Sci
Cruces-Párraga J, Muñoz-Jurado A, Escribano BM, Martín-Hersog FA, Triguero-Ortiz C, Carmona-Medialdea C, Túnez I, Caballero-Villarraso J, Agüera-Morales E.   +8 more
europepmc   +1 more source

Refining predictors of long-term NEDA-3 status in relapsing-remitting multiple sclerosis: insights from real-world data. [PDF]

Neurol Sci
Guerra T, Bianco A, Esposto C, Intini D, Amati F, Guglielmini G, Caputo F, Paolicelli D, Iaffaldano P.   +8 more
europepmc   +1 more source

Minimal association between Th1-specific responses to COVID-19 vaccines and SARS-CoV-2 breakthrough infections in multiple sclerosis patients receiving disease-modifying therapies. [PDF]

Front Immunol
Aiello A, Navarra A, Haggiag S, Ruggieri S, Cuzzi G, Vanini V, Salmi A, Notari S, Altera AMG, Meschi S, Colavita F, Cimini E, Tortorella C, Prosperini L, Quartuccio ME, Galgani S, Puro V, Maggi F, Grifoni A, Sette A, Nicastri E, Gasperini C, Goletti D.   +22 more
europepmc   +1 more source